更新于：2024-06-29
Toremifene Citrate
枸橼酸托瑞米芬
更新于：2024-06-29
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1995-03-31), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看首次获批时间轴
结构
分子式C32H36ClNO8 |
InChIKeyIWEQQRMGNVVKQW-OQKDUQJOSA-N |
CAS号89778-27-8 |
关联
48
项与 枸橼酸托瑞米芬 相关的临床试验枸橼酸托瑞米芬片在健康成年受试者中单次空腹状态及高脂餐后口服给药的随机、开放、两周期、两序列、交叉设计生物等效性试验方案
枸橼酸托瑞米芬片健康人体生物等效性研究
Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study
100 项与 枸橼酸托瑞米芬 相关的临床结果
登录后查看更多信息
100 项与 枸橼酸托瑞米芬 相关的转化医学
登录后查看更多信息
100 项与 枸橼酸托瑞米芬 相关的专利（医药）
登录后查看更多信息
715
项与 枸橼酸托瑞米芬 相关的文献（医药）2024-01-15Cancer research and treatment
Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes
Article
作者: Li, Lin ; Li, Zhigao ; Zhang, Ming ; Ren, Yanlv ; Qian, Cheng ; Wang, Jinsong ; Li, Zehao ; Chen, Kejin ; Ji, Dongchen ; Li, Xin ; Liu, Tong
Purpose Tamoxifen showed individual differences in efficacy under different CYP2D6*10 genotypes. Our study evaluated the prognosis of tamoxifen or toremifene in hormone receptor (HR)–positive breast cancer patients under different genotypes.Materials and Methods CYP2D6*10 genotypes of HR-positive breast cancer patients were determined by Sanger sequencing, and all the patients were divided into tamoxifen group or toremifene group.Results A total of 268 patients with HR-positive breast cancer were studied. The median follow-up time was 72.0 months (range, 5.0 to 88.0 months). Of these, 88 (32.9%), 114 (42.5%), and 66 (24.6%) patients had C/C, C/T, and T/T genotypes, respectively. Among patients who received tamoxifen (n=176), the 5-year disease-free survival (DFS) rate in patients with C/C and C/T genotype was better than that in patients with T/T genotype, and the difference was statistically significant (p < 0.001 and p=0.030, respectively). In patients receiving toremifene, CYP2D6*10 genotype was not significantly associated with DFS (p=0.325). Regardless of genotypes, the 5-year DFS rate was higher in patients treated with toremifene than in patients with tamoxifen (91.3% vs. 80.0%, p=0.011). Compared with tamoxifen, toremifene remained an independent prognostic marker of DFS in multivariate analysis (hazard ratio, 0.422; p=0.021). For all the 180 patients with CYP2D6*10 C/T and T/T genotypes, the 5-year DFS rate was significantly higher in the toremifene group than in the tamoxifen group (90.8% vs. 70.1%, p=0.003).Conclusion Toremifene may be an alternative adjuvant endocrine therapy for patients with CYP2D6*10 mutant genotypes.
2024-01-01Current medical imaging
Endometrial Adenofibroma in a Patient Receiving Toremifene: A Case Report
作者: Li, Tao ; Li, Lu ; Huang, Li-Zhao ; Liu, Gang
INTRODUCTION:
Adenofibroma is a rare benign Müllerian mixed tumor composed of epithelial and mesenchymal cells. This tumor may occasionally be associated
with toremifene therapy which is used as an adjuvant drug for breast cancer.
CASE PRESENTATION:
We describe a case of a 55-year-old woman with adenofibroma of the endometrium. This patient was receiving toremifene after surgery and
neoadjuvant chemotherapy for breast cancer. She underwent a total abdominal hysterectomy and bilateral salpingectomy. There was no evidence of
tumor residual or recurrence at 32 months of MRI follow-up.
CONCLUSION:
In conclusion, we report a rare case of endometrial adenofibroma in a patient receiving toremifene. It must be borne in mind that long-term
toremifene therapy may increase the frequency of endometrial neoplasms.
2023-12-01Gan to kagaku ryoho. Cancer & chemotherapy
[Elderly Advanced Breast Cancer Effectively Treated with Locoregional Therapy-A Case Report].
Article
作者: Adachi, Keita ; Kubota, Hitomi ; Suzuki, Shuhei ; Hirano, Tomohiro ; Sakurai, Kenichi ; Nagae, Junko
We report a case of advanced breast cancer in an elderly patient effectively treated with locoregional therapy. The patient was an 81-year-old woman who presented with an increasing right breast lump. The tumor was 55 mm in diameter, accompanied by fixation to pectoral muscle. A core needle biopsy for right breast tumor led to a diagnosis of mucinous carcinoma, positive for estrogen receptor(ER)and progesterone receptor(PgR), negative for HER2/neu. The Ki-67 positive cell index was 10%. A bone scintigraphy revealed multiple bone metastases, so, we confirmed the diagnosis as T4cN2aM1, Stage Ⅳ. She initiated endocrine therapy by letrozole. By changing the endocrine therapy to toremifene followed by fulvestrant, the therapy achieved a partial response. However, the size of the primary tumor increased accompanied by bleeding, and surgical resection of the right breast was performed for local control. The locoregional surgery was effective, improving the patient's quality of life. She was administered lapatinib as anti-HER2 therapy in addition to the endocrine therapy. Two years and 6 months after surgery, there has been no worsening of bone metastasis or appearance of visceral metastasis.
100 项与 枸橼酸托瑞米芬 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 转移性乳腺癌 | 美国 | 1997-05-29 | |
| 乳腺癌 | 日本 | 1995-03-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 癌前状态 | 临床3期 | 美国 | 2005-01-01 | |
| 癌前状态 | 临床3期 | 阿根廷 | 2005-01-01 | |
| 癌前状态 | 临床3期 | 加拿大 | 2005-01-01 | |
| 前列腺上皮内瘤变 | 临床3期 | 美国 | 2005-01-01 | |
| 前列腺上皮内瘤变 | 临床3期 | 阿根廷 | 2005-01-01 | |
| 前列腺上皮内瘤变 | 临床3期 | 加拿大 | 2005-01-01 | |
| 骨折 | 临床3期 | 美国 | 2003-10-01 | |
| 骨折 | 临床3期 | 墨西哥 | 2003-10-01 | |
| 骨质疏松症 | 临床3期 | 美国 | 2003-10-01 | |
| 骨质疏松症 | 临床3期 | 墨西哥 | 2003-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,589 | Placebo | 鹽簾簾願構淵齋選選鹽(鏇膚糧觸顧衊淵願顧選) = 窪窪範淵蓋積繭鑰壓鑰 窪餘襯餘構餘積網醖鹽 (窪糧糧鑰願衊簾網鹽範, 淵廠積鹽製顧襯鏇餘餘 ~ 衊簾壓醖網獵艱壓繭糧) 更多 | - | 2023-06-12 | ||
临床4期 | 绝经前乳腺癌 辅助 | 92 | 淵網構膚餘襯艱鑰襯鏇(鬱築選觸遞遞鏇積鹽衊) = 願蓋簾獵醖構鑰鹹簾襯 鏇範窪範顧鑰築鏇廠衊 (壓顧夢繭鬱窪觸選鏇鬱 ) 更多 | - | 2020-07-16 | ||
淵網構膚餘襯艱鑰襯鏇(鬱築選觸遞遞鏇積鹽衊) = 蓋遞餘鹽範遞鹽選襯餘 鏇範窪範顧鑰築鏇廠衊 (壓顧夢繭鬱窪觸選鏇鬱 ) 更多 | |||||||
临床3期 | - | 1,589 | 願衊網顧鹹觸構網簾鬱(鑰窪餘襯壓獵網夢鏇網) = 網鏇鑰製鹽獵膚蓋廠網 獵膚遞窪蓋蓋鏇壓衊選 (製鑰簾製範憲夢繭獵糧 ) 更多 | - | 2013-02-10 | ||
Placebo | 願衊網顧鹹觸構網簾鬱(鑰窪餘襯壓獵網夢鏇網) = 糧顧製網範膚糧選鹽艱 獵膚遞窪蓋蓋鏇壓衊選 (製鑰簾製範憲夢繭獵糧 ) 更多 | ||||||
临床3期 | 646 | 醖鏇構餘淵願築構蓋襯(製鹽衊廠糧製膚顧鹹膚) = 獵簾糧網衊願願餘衊膚 積窪廠網蓋構選選糧膚 (衊觸壓淵衊網鏇廠鏇遞, -1.5 ~ 75.0) 更多 | 积极 | 2013-01-01 | |||
Placebo | 醖鏇構餘淵願築構蓋襯(製鹽衊廠糧製膚顧鹹膚) = 鑰襯糧夢壓鬱選襯鹽鹽 積窪廠網蓋構選選糧膚 (衊觸壓淵衊網鏇廠鏇遞 ) 更多 | ||||||
N/A | 27 | 獵製淵顧醖艱繭構鹽壓(夢膚鹽顧鬱願夢構艱糧) = 構觸築廠簾選衊窪繭範 獵鏇餘夢齋膚顧網夢糧 (衊艱獵鑰廠壓構顧廠製 ) 更多 | - | 2011-05-20 | |||
临床3期 | - | 顧鏇膚獵製醖遞窪淵鹽(鬱膚構夢餘鬱淵糧壓鏇): relative risk reduction = 79.5 (95% CI, 29.8 ~ 94.0) | 积极 | 2010-05-20 | |||
Placebo | |||||||
N/A | - | 1,284 | 積鑰繭鹹衊觸窪膚鏇醖(膚窪築觸遞膚範醖願衊): OR = 0.59 (95% CI, 0.36 ~ 1.0), P-Value = <0.05 | - | 2010-04-01 | ||
Placebo | |||||||
临床3期 | - | 1,382 | 鏇醖淵鏇網構夢網鬱壓(願衊鹹網夢鹹壓網膚蓋) = 網選窪憲鏇鹹鹽鏇淵鏇 積願築鏇憲願鑰選鑰築 (遞糧顧襯廠顧網鏇鹹糧 ) 更多 | - | 2009-05-20 | ||
N/A | 13 | 鏇願築廠齋襯憲鑰餘繭(憲壓餘醖餘鏇獵廠艱製) = 鹽鹽衊願繭齋選鹹廠淵 衊窪獵夢網夢積醖獵醖 (衊鹹蓋觸觸願鹹襯廠選 ) 更多 | 积极 | 2005-06-01 | |||
临床2期 | 乳腺癌 新辅助 | - | 襯鏇膚淵觸構鹽憲繭網(壓醖襯築顧窪醖繭鏇願) = 糧構簾齋積遞衊鏇壓壓 餘選艱壓齋觸範鹽餘觸 (鏇廠蓋積餘鹽築憲遞艱, 28 ~ 58) | - | 2004-07-15 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用